Keyword: Mersana Therapeutics

Regulatory officials put enrollment in the XMT-1522 breast cancer trial on hold in July after learning of the death of a participant.

The FDA has placed a partial hold on Mersana’s lead candidate XMT-1522 after a patient death in a phase 1 trial, causing its shares to plunge.

Andrew Witty will lead Optum as CEO, Novartis' operations lead André Wyss steps down, Gilead bids farewell to longtime R&D lead Norbert Bischofberger.

Mersana Therapeutics is capitalizing on a buoyant period with a filing for a $75 million IPO to advance its antibody-drug conjugates (ADCs) for cancer through and into the clinic.

Mersana Therapeutics has teed up its first clinical program for the lead antibody drug conjugate in its pipeline, gaining $33 million in a new round to fund the work.